Avinger, Inc. (AVGR)
$
0.47
-0.12 (-25.53%)
Key metrics
Financial statements
Free cash flow per share
-6.5432
Market cap
1.5 Million
Price to sales ratio
0.2087
Debt to equity
1.4439
Current ratio
1.2085
Income quality
0.7820
Average inventory
3.9 Million
ROE
-54.2536
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Avinger, Inc., a commercial-stage medical device company, focuses on designing, manufacturing, and marketing a suite of image-guided and catheter-based systems for the treatment of peripheral arterial disease (PAD) in the United States and internationally. The company has developed a lumivascular platform that integrates optical coherence tomography visualization with interventional catheters, enabling real-time intravascular imaging during PAD procedures. Among its product offerings are the Lightbox imaging consoles and the Ocelot family of catheters, which help physicians navigate total blockages in arteries. Additionally, there is Pantheris, an image-guided atherectomy device that allows for precise removal of arterial plaque in patients with PAD. Its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, utilize a proprietary rotational spinning technique, allowing physicians to switch between passive and active modes while crossing a CTO. The company is also advancing its IMAGE-BTK system for treating PAD lesions located below the knee. Avinger markets its innovative products to interventional cardiologists, vascular surgeons, and interventional radiologists. The net total of other income and expenses is -$1,685,000.00 reflecting non-core financial activities. The company achieved a revenue of $7,652,000.00 indicating its niche market focus. The EBITDA ratio is -$2.14 highlighting the company's operational efficiency, and its operating expenses amount to $18,638,000.00 encompassing various operational costs incurred. Furthermore, the company incurred an interest expense of $1,719,000.00 reflecting its debt servicing obligations. In the financial landscape, the stock is affordable at $0.47 making it suitable for budget-conscious investors. Despite having a low average trading volume of 3,256,799.00 which indicates lower market activity, Avinger retains a market capitalization of $1,515,364.00 classifying it as a small-cap player. It is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape. In addition, Avinger belongs to the Healthcare sector, which drives innovation and growth. These facets underscore the company's commitment to advancing healthcare solutions while navigating its financial and operational goals.
What is Avinger, Inc. (AVGR)'s stock forecast?
Analysts predict Avinger, Inc. stock to fluctuate between $0.36 (low) and $4.37 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Avinger, Inc.'s market capitalization?
As of 2025-02-14, Avinger, Inc.'s market cap is $1,515,364, based on 3,196,970 outstanding shares.
How does Avinger, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Avinger, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Avinger, Inc. (AVGR) stock?
To buy Avinger, Inc. (AVGR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AVGR. Place an order (Market, Limit, etc.).
What is the best time to invest in Avinger, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Avinger, Inc. stock ever split?
Avinger, Inc.'s last stock split was 1:15 on 2023-09-13.
How did Avinger, Inc. perform in the last earnings report?
Revenue: $7,652,000 | EPS: -$23.31 | Growth: -44.27%.
Where can I find Avinger, Inc.'s investor relations reports?
Visit https://avinger.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Avinger, Inc.?
You can explore historical data from here
What is the all-time high and low for Avinger, Inc. stock?
All-time high: $3,013,200 (2015-12-28) | All-time low: $0.36 (2025-02-06).
What are the key trends affecting Avinger, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
3 months ago
SANTA CLARA, CALIFORNIA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- On February 10, 2025, Avinger, Inc., a Delaware Corporation (“Avinger” or the “Company”), entered into a general assignment for the benefit of creditors (the “Assignment”) in favor of Avinger (assignment for the benefit of creditors), LLC, a California limited liability company (the “Assignee”).
seekingalpha.com
6 months ago
Avinger, Inc. (NASDAQ:AVGR ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Matthew Kreps - Investor Relations Jeffrey Soinski - Chief Executive Officer Nabeel Subainati - Principal Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and welcome to the Avinger Third Quarter 2024 Results Conference Call.
zacks.com
6 months ago
Avinger (AVGR) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $2.03. This compares to loss of $2.92 per share a year ago.
accesswire.com
6 months ago
Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024. Third Quarter and Recent Highlights Reported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.
accesswire.com
7 months ago
REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
accesswire.com
7 months ago
REDWOOD CITY, CA / ACCESSWIRE / October 24, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease hosted a physician-focused webinar entitled, "New Approaches to Treating Peripheral Artery Disease (PAD) Below-the-Knee (BTK) and Promising New BTK Data." A recording of the webinar may be accessed at https://pages.avinger.com/webinar-new-approaches-to-treating-btk-pad.
accesswire.com
8 months ago
REDWOOD CITY, CA / ACCESSWIRE / September 18, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the issuance of a new U.S. patent and the allowance of five additional U.S. patents that are expected to issue over the next four months. These patents expand intellectual property protection for Avinger's proprietary image-guided system and devices for both peripheral and coronary applications.
zacks.com
9 months ago
Avinger (AVGR) fully launches Pantheris LV, the first image-guided atherectomy system for large vessels, thus enhancing peripheral artery disease treatment with advanced technology.
accesswire.com
9 months ago
REDWOOD CITY, CA / ACCESSWIRE / August 20, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced full commercial launch of the Pantheris LV image-guided directional atherectomy system. With the initiation of full commercial launch, all current and prospective accounts can now order the Pantheris LV device, a line extension of the first and only image-guided atherectomy device for the treatment of peripheral artery disease (PAD).
seekingalpha.com
9 months ago
Avinger, Inc. (AVGR) Q2 2024 Earnings Call Transcript
See all news
